Compugen Advances COM701 in Trial for Ovarian Cancer at ESMO Congress

Compugen Ltd (CGEN), a clinical-stage cancer immunotherapy company, is making significant strides in the fight against relapsed platinum-sensitive ovarian cancer. Recently, the company presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress in Copenhagen, focusing on its promising therapy, COM701. This innovative anti-PVRIG antibody represents a step forward in a treatment landscape that currently lacks a standard maintenance therapy for this challenging condition. With the poster titled "MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)," Compugen aims to demonstrate the potential of COM701 to fill this treatment gap.

Innovative Therapy on the Horizon

Dr. Eran Ophir, CEO of Compugen, expresses optimism regarding the trial's design and the safety profile of COM701. He highlights that recent findings from Phase 1 studies indicate promising anti-tumor activity and manageable tolerability among patients who have undergone extensive previous treatments. As the company prepares for the initial efficacy results, expected by Q1 2027, stakeholders remain keen on understanding how COM701 can improve outcomes for patients facing dire circumstances without effective options.

Expanding Pipeline and AI-Driven Discovery

Compugen's broader therapeutic pipeline includes a range of clinical-stage programs beyond COM701, showcasing its commitment to pioneering immuno-oncology therapies. This includes COM902, rilvegostomig, and GS-0321, which are in various stages of development. Additionally, leveraging its Unigen™ computational discovery platform, Compugen leverages AI and machine learning to identify novel drug targets and therapeutics, solidifying its position as an innovator in the rapidly evolving field of cancer treatments.

Commitment to Transparency and Knowledge Sharing

The presentation poster detailing the MAIA-ovarian trial will soon be accessible on the company's website, allowing for further transparency and knowledge sharing within the scientific community.